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Abstract The mitogen-activated protein kinase-activated
protein kinase-5 (MK5) resides predominantly in the
nucleus of resting cells, but p38
MAPK, extracellular signal-
regulated kinases-3 and -4 (ERK3 and ERK4), and protein
kinase A (PKA) induce nucleocytoplasmic redistribution of
MK5. The mechanism by which PKA causes nuclear export
remains unsolved. In the study reported here we demon-
strated that Ser-115 is an in vitro PKA phosphoacceptor
site, and that PKA, but not p38
MAPK, ERK3 or ERK4, is
unable to redistribute MK5 S115A to the cytoplasm.
However, the phosphomimicking MK5 S115D mutant
resides in the cytoplasm in untreated cells. While p38
MAPK,
ERK3 and ERK4 fail to trigger nuclear export of the kinase
dead T182A and K51E MK5 mutants, S115D/T182A and
K51E/S115D mutants were able to enter the cytoplasm of
resting cells. Finally, we demonstrated that mutations in
Ser-115 affect the biological properties of MK5. Taken
together, our results suggest that Ser-115 plays an essential
role in PKA-regulated nuclear export of MK5, and that it
also may regulate the biological functions of MK5.
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Abbreviations
ERK Extracellular signal-regulated kinase
MAPK Mitogen-activated protein kinase
MK5 Mitogen-activated protein kinase-activated
protein kinase 5
MKK6 MAPK kinase 6
NES Nuclear export signal
NLS Nuclear localization signal
PC12 Rat phaeochromocytoma cells
PKA Protein kinase A or cAMP-dependent protein
kinase
Introduction
Mitogen-activated protein kinase (MAPK) pathways
mediate cellular responses to a wide variety of extracellular
signalling molecules. In mammalian cells, they participate
in the regulation of processes such as proliferation, dif-
ferentiation, survival/apoptosis, development, metabolism,
motility, and gene expression. Seven distinct mammalian
MAPK pathways have been identiﬁed. The typical MAPK
pathways, represented by the ERK1/2, ERK5, JNK, and
p38
MAPK modules consist of a cascade of three consecutive
phosphorylation events exerted by a MAPK kinase kinase
(MAPKKK), a MAPK kinase (MAPKK), and a MAPK.
The atypical MAPKs ERK3/4, ERK7 and ERK8 represent
the less-characterized MAPK pathways [1–9]. MAPK not
only target nonprotein kinase substrates, but they can also
phosphorylate other protein kinases designated as MAPK-
activated protein kinases (MAPKAPK). The MAPKAPKs
include the ribosomal-S6-kinases (RSK1-4), the MAPK-
interacting kinases (MNK1 and 2), the mitogen- and stress-
activated kinases (MSK1 and 2), and the MAPKAPK
(MK2, 3 and 5) subfamilies [10–15].
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protein kinase (PRAK) were originally described as in vitro
p38 substrates that could be activated by p38 through
phosphorylation of Thr-182 [16–20]. The biological func-
tions of MK5 are poorly understood, as MK5 knockout
mice bred onto different backgrounds display either no
obvious phenotype or embryonic lethality [10, 20]. Recent
studies have demonstrated that MK5 is involved in ras-
induced senescence, tumour suppression, inhibition of cell
proliferation, rearrangements of the cytoskeleton, and
anxiety-related behaviour [18, 21–25], and have identiﬁed
ERK3, ERK4, p53, Hsp27 and 14-3-3e as bona ﬁde sub-
strates. [20, 21, 25–29]. MK5-mediated inhibition of
proliferation may depend on MK5’s ability to stimulate the
transcriptional activity of p53, and subsequent increased
expression of the cyclin-dependent protein kinase inhibitor
p21
Cip1/Waf1, a target gene of p53 [21, 24]. MK5 seems to
exert its role in F-actin dynamics through phosphorylation
of Hsp27, an event in part controlled by 14-3-3e [25, 29].
The biological relevance of the other interactions remains
incompletely understood.
Several groups have shown that although endogenous
and ectopically expressed MK5 predominantly reside in the
nucleus of resting cells, MK5 actually shuttles between
the nucleus and the cytoplasm [19, 20, 22, 26–28, 30]. The
opposing activities of a functional nuclear export signal
(NES) and a nuclear localization signal (NLS) may deter-
mine the subcellular distribution of MK5. Different studies
have demonstrated that the interaction with other proteins
inﬂuences the accessibility of the NLS/NES motifs to the
import/export system and therefore regulates the location
of MK5 [19, 30]. MK5 contains a putative p38
MAPK
docking site that overlaps with the NLS (Fig. 1) and in
vitro interaction studies have conﬁrmed that MK5 can
interact with p38a and p38b [19, 24, 30–32]. It is still
controversial whether p38
MAPK and MK5 form direct
contact in vivo as they seem to interact very weakly in
yeast two-hybrid assays [20, 26], while tandem afﬁnity
puriﬁcation studies have failed to detect MK5-p38
MAPK
complexes in HEK 293 cells [33]. However, both Tanoue
et al. and Li et al. were able to immunoprecipitate MK5-
p38
MAPK complexes from NIH3T3 cells overexpressing
these proteins [24, 32]. Stimulation of endogenous p38
MAPK
with known activators such as sorbitol, sodium arsenite and
TNFa, or overexpression of p38
MAPK causes subcellular
redistributionofMK5.Overexpressionofap38
MAPKmutant
unable to bind MK5 fails to redistribute MK5, and similarly
mutation in the p38
MAPK docking of MK5 abrogates
p38
MAPK-mediated subcellular redistribution of the protein
[19, 24, 30]. These observations suggest that localization of
MK5 is affected by physical interaction with p38
MAPK [19,
24, 30]. The atypical MAPKs ERK3 and ERK4 can interact
with MK5 in vitro and in vivo and overexpression of both
proteins has been shown to retain MK5 in the cytoplasm.
BindingofERK3orERK4toMK5isrequiredforitsnuclear
export [20, 26–28, 34]. The conformation of MK5 may also
inﬂuence its subcellular location. In such a scenario, phos-
phorylation of Thr-182 may induce allosterical changes in
MK5, thereby exposing the NES and triggering nuclear
export of the phosphoMK5 [10, 19].
We have recently shown that activation of the cAMP/
PKA signalling pathway or overexpression of the catalytic
Ca subunit induces nuclear export of MK5. The kinase
activities of both PKA and MK5 are required for nucleo-
cytoplasmic translocation. PKA can phosphorylate MK5,
but the target sites have not been mapped, nor has the effect
of mutations in the putative phosphorylation sites on the
location of the protein been investigated [22]. Here we
report that PKA can phosphorylate MK5 at Ser-115 and
that mutations in this site interfere with the subcellular
distribution of the protein ruled by PKA, but not by
p38
MAPK, ERK3 or ERK4. Hence, PKA-mediated nuclear
export of MK5 differs from the mechanism described for
the other interaction partners of MK5.
Fig. 1 Schematic
representation of the structure of
MK5. The protein consists of
473 amino acids. The catalytic
domain and the NES and NLS
are shown. The
phosphoacceptor site in the
activation loop (T182) is
indicated, as well as the serine
residue (S115) that was
identiﬁed in this work as a PKA
site. The primary sequence of
the NES and NLS are given.
The p38 docking site, which
overlaps with the NLS, is
indicated
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Materials
Forskolin and sodium arsenite were purchased from Sigma-
Aldrich (St. Louis, MO). Lipofectamine, cell culture
medium and serum were obtained from Invitrogen Life
Technologies (Carlsbad, CA). Phospho-PKA substrate
(RRXS/T) antibody and Myc-tag Alexa Fluor 647 conju-
gate mouse monoclonal antibody were obtained from Cell
Signaling (catalogue number 9624 and 2233, respectively;
Danvers, MA). Anti-PRAK A-7 antibodies (catalogue
number sc-46667) and anti PKA-Ca C-20 antibodies (cata-
logue number sc-903) were both from Santa Cruz (Santa
Cruz, CA), while anti-actin antibody was purchased from
Sigma-Aldrich (catalogue number A2066). The alkaline
phosphatase-conjugated secondary antibodies and the oli-
gonucleotides were from Sigma. CDP-star and MagicMark
western standard were from Applied Biosystems (CA) and
Invitrogen Life Technologies, respectively. Activated
PRAK was from Millipore Upstate (Billerica, MA), while
puriﬁed PKA was from Promega Corporation (Madison,
WI). Leptomycin B was from Sigma-Aldrich (St. Louis,
MO). The MK5 GGELFHRISQ peptide and the MK5
S115A GGELFHRIAQ peptide were synthesized by
Johannes Eksteen (Institute for Pharmacy, University of
Tromsø). The F-actin probe Alexa Fluor 594 Phalloidin
was purchased from Invitrogen Life Technologies (cata-
logue number A12381).
Plasmids
The plasmids encoding MKK6 E/E, p38
MAPK, and the
EGFP fusion proteins with wild-type MK5 and the MK5
mutants K51E, T182A and L337A have all been previously
described [19, 26]. Expression plasmids for pEGFP-MK5
S115A and pEGFP-MK5 S115D were generated by site-
directed mutagenesis using pEGFP-MK5 DNA as template.
Only one strand of the primers used in the mutagenesis
reaction is given (the mutated nucleotides are underlined):
S115A, 50-GTC-TGT-GTG-AAG-AAA-GCC-ACT-CAA-
GAA-CGG-30; S115D, 50-GTC-TGT-GTG-AAG-AAA-
GAC-ACT-CAA-GAA-CGG-30. The pEGFP-MK5 S115D/
T182A expression plasmid was generated by site-directed
mutagenesis using pEGFP-MK5 T182A as template and
the S115D primers mentioned above. Plasmid pEGFP-
MK5 S115D/L337A was obtained by site-directed muta-
genesis using pEGFP-MK5 L337A as template and the
S115D primers. Plasmid pEGFP-MK5 K51E/S115D was
generated by site-directed mutagenesis of pEGFP-MK5
K51E [19] with the S115D primers described above. The
GST-MK5102–155 expression plasmid was generated by
amplifying the coding region of MK5 spanning amino acid
residues 102–155 using the primers 50-CTC GAC TGT
TAA ATG GAT CCG AGA TGA TGG AAG-30 and
50-CAG AGA GTT ATC GTC GAC AAG CAG ATT TCC
AGG-30. The PCR fragment was thereafter digested with
BamHI and SalI and ligated into the BamHI and XhoI sites
of the GST vector pGEX-4T-1 (GE Healthcare). All plas-
mids were veriﬁed by sequencing and the expression levels
of all EGFP-MK5 mutants were similar to that of wild-type
EGFP-MK5 (results not shown). The pEGFP-MK2 plasmid
was kindly provided by Dr. Matthias Gaestel [35]. The
expression vector pEGFP-MK2insD was obtained by site-
directed mutagenesis using the complementary primers
(only one primer is given): 50-GCT-CTT-TAG-TCG-AAT-
CGA-TCA-GGA-CCG-AGG-AGA-C-30. The chimeric
EGFP-MK2/mk5, EGFP-MK2/mk5 S115D, and EGFP-
MK2/mk5 S115A were created by site-directed mutagen-
esis. First, EGFP-MK2/mk5 S115D was generated using
the complementary oligonucleotides (only one strand is
given): 50-GGT-GGA-GAG-CTC-TTT-CAT-CGA-ATC-
GAT-CAG-CAC-CGA-CAC-TTC-ACA-GAA-AGA-GAG-
GCG-TCA-GAG-ATC-ATG-AAG-30. This construct was
then used to obtain EGFP-MK2/mk5 and EGFP-MK2/mk5
S115A using the primers (only one strand is shown):
50-CTC-TTT-CAT-CGA-ATC-AGC-CAG-CAC-CGA-CA
C-TTC-30 and 50-CTC-TTT-CAT-CGA-ATC-GCT-CAG-
CAC-CGA-CAC-TTC-30, respectively. All plasmid con-
structs were veriﬁed by sequencing. The ERK3 expression
plasmid has been previously described [36], while the
ERK4 expression plasmid was a generous gift from Dr. Ole
Morten Seternes [28].
Cell culture and transfection
PC12 cells were purchased from the European Collection
of Cell Cultures (ECACC; Salisbury, UK). The cells were
maintained in RPMI 1640 supplemented with 10% horse
serum (Gibco) and 5% fetal bovine serum, 2 mM L-gluta-
mine, penicillin (110 U/ml) and streptomycin (100 lg/ml).
Cells were transfected using a Nucleofection kit (Amaxa)
according to the manufacturer’s instructions. HEK293 cells
(ATCC CRL-1573) and HeLa cells (ATCC CCL-2) were
purchased from the American Type Culture Collection
(LGC Standards, Boras, Sweden) and maintained in
Eagle’s minimum essential medium supplemented with
10% fetal calf serum, 2 mM L-glutamine (110 U/ml) and
streptomycin (100 lg/ml). HeLa cells also received
19 nonessential amino acids (Invitrogen).
Western blotting
For detection of coimmunoprecipitates and MK5, samples
were analysed by SDS-PAGE NuPage 4–12% Bis-Tris
SDS-PAGE (Invitrogen) according to the manufacturers
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(Millipore, Billerica, MA). Immunoblotting was performed
by ﬁrst blocking the membrane with phosphate-buffered
saline (PBS) with 0.1% Tween-20 (PBS-T; Sigma-Aldrich)
containing 10% (w/v) dried skimmed milk for 1 h and
probed with the appropriate primary antibody. After three
washes, the membrane was incubated with the appropriate
secondary antibody for 1 h. After four washes, antigen–
antibody complexes were visualized using CDP Star
(Tropix, Bedford, MA) substrate and a Lumi-Imager F1
from Roche (Basel, Switzerland).
Cell staining and microscopy
Cells were rinsed twice with PBS and ﬁxed for 10 min with
4% paraformaldehyde. Next, the cells were washed twice
with PBS and then permeabilized for 10 min with 0.1%
Triton X-100. The cells were then washed with PBS and
examined using confocal laser-scanning Zeiss LSM 510
META and Leica SP5 microscopes. Cell nuclei were
visualized by DRAQ5 staining (Biostatus, Shepshed, UK).
Routinely 50 cells or more were examined for subcellular
localization, and representative images are shown in the
Results. The expression plasmid for the HSP27-3A mutant
has been previously described [25].
GST-fusion protein puriﬁcation
GST fusion proteins were puriﬁed from Escherichia coli
BL21 extracts using glutathione–agarose beads as previ-
ously described [19], and the GST moiety was removed
from the GST beads using thrombin according to the
instructions of the manufacturer. Protein concentrations
were measured using a Bio-Rad Protein Assay kit (Bio-Rad
Laboratories, Hercules, CA).
In vitro kinase assays
Peptide arrays were synthesized on cellulose paper using a
MultiPep automated multiple peptide synthesizer (INTA-
VIS Bioanalytical Instruments). For phosphorylation,
membranes were wetted brieﬂy in ethanol prior to incu-
bation in phosphorylation buffer (20 mM Hepes, pH 7.4,
100 mM NaCl, 5 mM MgCl2, 1 mM DTT and 0.2 mg/ml
BSA) for 1 h at room temperature. The array was then
incubated at 4C overnight in blocking buffer (phosphory-
lation buffer containing 1 mg/ml BSA and 100 lM ATP).
Phosphorylation was initiated by incubating the membrane
in the presence of 70 U recombinant PKA catalytic subunit
(Promega) in 20 ml phosphorylation buffer containing
50 lM ATP and 0.37 MBq [c-
32P]ATP for 30 min at 30C
with agitation. The membrane was washed extensively in
1 M NaCl followed by washes in 5% H3PO4 and dried
down [37]. The phosphorylated membrane was then visu-
alized using a BioImaging Analyser (FUJIFILM BAS-
5000). MK5102–155 by PKA was phosphorylated in vitro as
previously described [22]. For competition, 25-, 2.5, and
0.25-fold molar excesses of peptide were used.
Transient transfection studies and luciferase assay
For transient transfection studies, HEK293 cells were pla-
ted at 3 9 10
5 cells per well in a six-well plate and plasmid
DNA was transfected using lipofectamine. The plasmids
pGAL4-E1b-LUC and pGAL-p53 have been previously
described [38]. Luciferase activity was monitored using
a Promega Luciferase 1000 assay system as described
previously [22]. Each transfection was performed inde-
pendently in triplicate and the experiments were repeated
four times.
Results
PKA phosphorylates MK5 at Ser-115 in vitro
Our previous studies had shown that MK5 speciﬁcally
interacts with the catalytic subunit of PKA and that PKA
can phosphorylate MK5 in vitro. Active PKA also causes
MK5 to translocate from the nucleus to the cytoplasm and
this process requires the activity of both kinases. The PKA
phosphoacceptor site(s) on MK5 were, however, not
mapped [22]. Computational prediction revealed that serine
residue 115 might be a putative PKA site. This site is
encompassed in the HRIS/T motif, which remotely
resembles the PKA phosphorylation motif RRXS/T [39].
Ser-115 is not conserved in MK2 and MK3 (Fig. 2a) and
may explain why we did not ﬁnd phosphorylation of MK2
by PKA in vitro [22]. To check whether Ser-115 of MK5
could be phosphorylated by PKA, we ﬁrst performed an in
vitro kinase assay using a peptide array. By this method,
we were indeed able to conﬁrm that PKA phosphorylated a
peptide encompassing Ser-115 in vitro (Fig. 2a). In addi-
tion to phosphorylation of this peptide, we observed
weaker phosphorylation of other peptide sequences on the
membrane. Next, we examined whether puriﬁed PKA
could phosphorylate recombinant MK5. As MK5 possesses
autophosphorylation activity which would interfere with
the interpretation of the data, we generated a MK5 frag-
ment encompassing residues 102–155 as a GST fusion
protein and removed the GST moiety by cleavage with
thrombin. The puriﬁed catalytic subunit of PKA (Ca)
clearly phosphorylated the MK5102–155 fragment (Fig. 2b).
This phosphorylation was competed out by a MK5 peptide
fragment containing Ser-115, but not by a corresponding
fragment in which Ser-115 had been replaced by Ala
850 S. Kostenko et al.(Fig. 2b). These results indicate that Ser-115 represents an
in vitro PKA acceptor site.
Ser-115 is necessary for PKA-induced
nucleocytoplasmic distribution of MK5
Because activation of the cAMP/PKA pathway by the
cAMP-elevating agent forskolin has been shown to trigger
a transient nuclear export of MK5 [22], we wanted to
investigate whether Ser-115 is implicated in this process.
We therefore generated an EGFP-MK5 S115A mutant and
compared its subcellular distribution in resting and for-
skolin-treated PC12 cells. In resting cells, this mutant
resided predominantly in the nucleus (Fig. 3a). In contrast
to wild-type MK5, forskolin did not cause nuclear export of
EGFP-MK5 S115A (Fig. 3b). Similar results were obtained
in HeLa cells (results not shown). To exclude the possi-
bility that activated PKA failed to cause cytoplasmic
redistribution of MK5 S115A because the catalytic Ca
subunit could no longer interact with this mutant, we per-
formed coimmunoprecipitation studies. HEK293 cells were
transfected with expression plasmids for EGFP-MK5 or
EGFP-MK5 S115A and the cells were left untreated or
stimulated with forskolin for 30 min. EGFP-MK5 fusion
proteins were immunoprecipitated with antibodies directed
against MK5 and the immunoprecipitates were challenged
for the presence of Ca by using anti-Ca antibodies. Our
results showed that wild-type MK5 and MK5 S115A
interacted with Ca and that no major differences in inter-
action were observed as judged by the intensity of the
coimmunoprecipitated complexes (Fig. 4). Taken together,
these ﬁndings suggest that Ca can still interact with MK5
Fig. 2 PKA phosphorylates MK5 at serine residue 115 in vitro. a In
vitro kinase assay of a peptide array membrane that was spotted with
three amino acid overlapping oligopeptides 20 amino acids long that
spanned the complete MK5 protein. The autoradiographic exposure is
shown on the left and the phosphorylated peptide is encircled. The
right panel represents the Ponceau-stained membrane used for
the peptide kinase assay. The peptide spot corresponding to the
phosphorylated peptide is encircled. The sequence of the oligopeptide
that was vividly phosphorylated by PKA is given with serine residue
115 indicated in bold. Comparison of the corresponding sequences of
MK2 and MK3 reveals that S115 is not conserved in MK2 and MK3.
The identical amino acids in the three proteins are underlined. b In
vitro kinase assay on recombinant MK5102–155 fragment.
GST-MK5102–155 fusion protein was puriﬁed from E. coli and the
MK5 moiety was released by thrombin. The MK5 fragment was
incubated for 30 min at 30C with Ca in the presence of [c-
32P]ATP.
Decreasing amounts (25, 2.5, and 0.25 M excess) of wild-type or
S115A mutant competitor peptide encompassing amino acid residues
107–116 were added. Proteins were separated by polyacrylamide gel
electrophoresis and phosphorylation was visualized by autoradiogra-
phy. Bottom panel Coomassie blue staining ensured equal loading of
the proteins in each sample. The molecular masses (in kilodaltons) of
the protein marker are indicated
PKA-mediated MK5 nuclear export 851S115A but cannot direct nuclear export of this mutant. To
further assess whether phosphorylation of Ser-115 is nec-
essary for PKA-induced nuclear exclusion of MK5, we
generated the MK5 S115D mutant, which mimics consti-
tutive phosphorylation, and monitored its subcellular
location. This phosphomimicking substitution caused
EGFP-MK5 S115D to reside also in the cytoplasm of
untreated cells (Figs. 3a, d and 6). These results support the
assumption that PKA-mediated phosphorylation of MK5 at
Ser-115 is implicated in nuclear export of MK5.
Chimeric MK2 with the S115 motif behave as MK5
Both MK2 and MK5 reside predominantly in the nucleus
of untreated cells [19, 22, 27, 35]. However, we have
previously shown that PKA does not interact with nor
phosphorylate MK2 [22]. Moreover, we found that for-
skolin did not induce nuclear export of the EGFP-MK2
fusion protein (Fig. 5a). Interestingly, Ser-115 in MK5 is
encompassed in the motif RISQ, while the corresponding
sequence in MK2 and MK3 is RIQ, lacking an equivalent
of Ser-115 (Fig. 5b). To evaluate the importance of this
Ser-115 in PKA-induced nuclear export of MK5, we rea-
soned that a MK2 mutant with an insertion of Asp as a
phosphomimicking Ser-115 in the RIQ motif (= MK2insD)
may behave identically to MK5 S115D, i.e. with both
nuclear and cytoplasmic localizations in untreated cells.
Contrary to MK5 S115D, the EGFP-MK2insD mutant
remained exclusively in the nucleus of HeLa cells (Fig. 5c)
and HEK293 cells (results not shown). Alignment of
human and mouse MK5, MK2, and MK3 revealed differ-
ences in residues C-terminal to Ser-115 (Fig. 5b). To
Fig. 3 Phosphomimicking mutation of Ser-115 affects the subcellu-
lar distribution of EGFP-MK5 fusion protein in resting cells. a PC12
cells were transfected with expression plasmids for EGFP-tagged
MK5 (top panels), EGFP-tagged MK5 S115A (middle panels), or
EGFP-tagged MK5 S115D (bottom panels) and left untreated. b PC12
cells were transfected with expression plasmids for EGFP-MK5 or
EGFP-MK5 S115A fusion proteins. Cells were exposed 24 h after
transfection to 10 lM forskolin for 30 min and were then ﬁxed.
c PC12 cells were transfected with expression plasmids for EGFP-
MK5 S115D/T182A and left untreated. d Cells transfected with
plasmids encoding EGFP-tagged wild-type MK5, mutant MK5
S115D, MK5 K51E, or MK5 K51E/S115D. The subcellular location
of ectopically expressed MK5 variants was monitored by EGFP
ﬂuorescence (green channel), while the cell nuclei were visualized by
DRAQ5 staining (blue channel). On average 50 cells expressing
EGFP-MK5 were analysed and representative images are shown.
Similar results were obtained in independent experiments
852 S. Kostenko et al.examine the possible contribution of these residues in
PKA-triggered nuclear export, we constructed chimeric
MK2 containing the wild-type MK5, and MK5 S115D
sequences, to generate the fusion proteins EGFP-MK2/mk5
and EGFP-MK2/mk5 S115D, respectively. EGFP-MK2/
mk5 S115D behaved as EGFP-MK5 S115D because it was
detected in both the nucleus and cytoplasm of untreated
cells (Fig. 5d). Surprisingly, EGFP-MK2/mk5 was found
in both the nucleus and the cytoplasm, but was most
obvious in the cytoplasm. However, forskolin treatment
caused complete nuclear exclusion of EGFP-MK2/mk5
(Fig. 5d). Taken together, these results indicate that Ser-
115 is necessary but not sufﬁcient to control subcellular
distribution of MK5 in response to an activated PKA
pathway. Amino acids C-terminal to Ser-115 also con-
tribute to PKA-regulated subcellular distribution of MK5.
The PKA phosphomimicking S115D mutation restores
cytoplasmic shuttling of kinase dead MK5 mutants
Activated PKA was unable to induce nuclear export of the
kinase dead MK5 T182A mutant, which carries a substi-
tution in its activation loop [22]. This may indicate that the
kinase activity of MK5 is absolutely required for
subcellular translocation by PKA. The ﬁnding that another
kinase dead MK5 mutant (MK5 K51E) with a mutation in
the ATP-binding domain also remained in the nucleus after
forskolin treatment supports this assumption [19, 22]. This
prompted us to examine whether phosphomimicking of
Ser-115 could rescue nuclear export of the kinase dead
MK5 T182A and K51E mutants. We generated the MK5
S115D/T182A mutant and subcellular localization studies
of this mutant revealed a cytosolic location in untreated
cells (Fig. 3c). As could the MK5 S115D/T182A mutant,
the double MK5 K51E/S115D mutant was able to enter the
cytoplasm in untreated cells (Fig. 3d). Thus activated PKA
is unable to translocate kinase dead MK5 out of the
nucleus, yet kinase dead MK5 mutants carrying the phos-
phomimicking S115D substitution can leave the nucleus
(see ‘‘Discussion’’).
PKA-induced nuclear export of MK5 depends
on CRM1
Our earlier study showed that stress-induced nuclear export
of MK5 relies on a CRM1/NES-dependent mechanism
[19]. To test whether PKA-induced nuclear export of MK5
is dependent on CRM1, we treated cells with leptomycin B,
Fig. 4 Substitution of Ser-115 into Ala does not abrogate the
interaction between the catalytic subunit of PKA (Ca) and MK5.
HEK293 cells were transfected with expression plasmids for EGFP-
MK5 or EGFP-MK5 S115A and then either left untreated or
stimulated with 10 lM forskolin for 30 min. EGFP-MK5 fusion
proteins were immunoprecipitated (IP) from cell lysates using anti-
PRAK antibodies. These antibodies are directed against the human
homologue of MK5 and crossreact with MK5. The immunoprecip-
itates were then examined for the presence of Ca by western blot
(WB) with anti-Ca antibodies (lanes 5–8). The presence of Ca in the
immunocomplexes is indicated by the arrow. Total cell lysates (input
control) are shown in lanes 1–4. Bottom panel: to ensure equal
loading and expression of EGFP-MK5 and EGFP-MK5 S115A,
membranes were stripped and probed with anti-PRAK antibodies.
The position of EGFP-MK5 (EGFP-MK5 S115A) is indicated by the
arrow. The molecular mass (in kilodaltons) of the protein marker is
given
PKA-mediated MK5 nuclear export 853a selective inhibitor of CRM-1, prior to the addition of
forskolin. While forskolin caused nuclear export of EGFP-
MK5, leptomycin B prevented this forskolin-triggered
export (Fig. 6a). Leptomycin B exposure also strongly
reduced the predominant cytoplasmic localization of the
EGFP-MK5 S115D mutant in resting cells (Fig. 6a). Sub-
stitution of residue Leu-337 into Ala in the NES generated
a MK5 mutant that was unable to shuttle into the cytoplasm
[19], while this study demonstrated that the MK5 S115D
resides mainly in the cytoplasm (see Figs. 3a and 6). To
investigate the involvement of the NES of MK5 in the
cytoplasmic distribution of MK5 S115D, we constructed
the double EGFP-MK5 S115D/L337A mutant. In contrast
to MK5 S115D, this mutant was unable to shuttle to the
cytoplasm (Fig. 6b), suggesting that a functional NES is
required for PKA-mediated nuclear exclusion of MK5.
Taken together, these results indicate that nucleocytoplas-
mic translocation of MK5 by active PKA requires a
functional CRM1/NES mechanism.
ERK3- and ERK4-mediated nuclear export of MK5
does not require Ser-115
The atypical MAPK ERK3 and ERK4 are two genuine
substrates for MK5. ERK4 is predominantly found in the
cytoplasm, while ERK3 is distributed in the nucleus and
Fig. 5 Subcellular localization of MK2 and MK2/mk5 hybrids.
a EGFP-MK2 resides predominantly in the nucleus of untreated cells
and this subcellular localization is not changed upon activation of the
cAMP/PKA pathway by forskolin. Cells were treated with 50 lM
forskolin (FSK) for 30 min. b Alignment of the region spanning Ser-
115 in MK5 with the corresponding sequence in MK2. The insertion
of Asp (d) is highlighted in grey. c Insertion of a phosphomimicking
Asp in MK2 that corresponds to Ser-115 in MK5 does not affect the
subcellular localization of this MK2insD mutant. d Swapping
the MK2 domain with the MK5 motif encompassing Ser-115 changes
the subcellular localization of the MK2 from almost exclusively
nuclear to both cytoplasmic and nuclear for the MK2/mk5 hybrid
protein (top panels). Forskolin triggers nuclear exclusion of MK2/
mk5 (middle panels). The MK2/mk5 S115D mutant resides predom-
inantly in the cytoplasm of untreated cells (bottom panels). The EGFP
fusion proteins were visualized as described in the legend for Fig. 3.
On average 50 cells expressing EGFP-MK5 were analysed and
representative images are shown. Similar results were obtained in
independent experiments
854 S. Kostenko et al.cytoplasm [20, 26–28, 34, 40–42]. Coexpression of ERK3
(or ERK4) and MK5 in HeLa and HEK293 cells results in
exclusive cytoplasmic localization of ERK3 (or ERK4) and
MK5 [20, 26–28, 34, 40–42]. This ERK3-/ERK4-mediated
nuclear export of MK5 does not depend on the kinase
activity of MK5 as ectopic expression of both ERK3 and
ERK4 causes nuclear exclusion of the kinase dead MK5
T182A mutant [20, 26–28]. To test whether Ser-115 is
important for nucleocytoplasmic redistribution of MK5 by
ERK3 and ERK4, we cotransfected cells with either wild-
type MK5 or MK5 S115A and ERK3 or ERK4 and mon-
itored the subcellular distribution of MK5. ERK3, as well
as ERK4, was able to induce nuclear exclusion of both
EGFP-MK5 and EGFP-MK5 S115A when coexpressed in
HeLa cells (Fig. 7) or PC12 cells (results not shown). Thus
ERK3- and ERK4-mediated nuclear export of MK5 is
independent of the phosphorylation state of Ser-115.
p38
MAPK-mediated nuclear export of MK5 does
not require Ser-115 phosphorylation
Studies by us and others have shown that stimuli that acti-
vate the p38
MAPK pathway or activated p38
MAPK mutants
trigger cytoplasmic redistribution of MK5 [19, 24, 30]. This
encouraged us to investigate whether the phosphorylation
state of Ser-115 can interfere with p38
MAPK-mediated
Fig. 6 Both PKA-induced nucleocytoplasmic redistribution of MK5
and cytoplasmic residence of MK5 S115D are CRM1-dependent
processes. a HeLa cells were transfected with EGFP-MK5 (panels
A–I) or EGFP-MK5 S115D (panels J–O) and either pretreated with
5 ng/ml leptomycin B (LMB) for 1 h (panels G–I and M–O) or left
untreated. Cells were then exposed to 10 lM forskolin (FSK)
for 30 min (panels D–I and M–O) or left untreated (panels A–C and
J–O). b HeLa cells were transfected with EGFP-MK5 S115D or
EGFP-MK5 S115D/L337A expression plasmids. The latter contains a
mutation in the NES which renders this motif nonfunctional [19]. The
subcellular localization of the EGFP-MK5 fusion proteins was
monitored as described in the legend of Fig. 3. On average 50 cells
expressing EGFP-MK5 were analysed and representative images are
shown. Similar results were obtained in independent experiments
PKA-mediated MK5 nuclear export 855subcellular localization of MK5. Exposure of cells to
sodium arsenite, a potent activator of the p38
MAPK pathway,
resulted in nuclear export of EGFP-MK5 S115A (Fig. 8a).
Similarly, coexpression of the constitutive active MKK6
E/E mutant and p38
MAPK also caused an increase in cyto-
plasmic residence of EGFP-MK5 S115A (Fig. 8b).
These ﬁndings strongly suggest that p38
MAPK-regulated
subcellular localization of MK5 is independent of Ser-115
phosphorylation.
Mutations in Ser-115 affect the biological properties
of MK5
Because mutations in Ser-115 control the subcellular
localization of MK5, we decided to examine the effect of
these mutations on nuclear and cytoplasmic events
involving MK5. MK5 has been shown to stimulate the
transcriptional activity of p53 by direct phosphorylation of
p53 at Ser-37 [21]. As transcription is a nuclear process, we
Fig. 7 Overexpression of ERK3 and ERK4 induces nuclear export of
wild-type MK5 and the S115A mutant. HeLa cells were cotransfected
with either expression plasmids for EGFP-MK5 or EGFP-MK5
S115A alone, or cotransfected with myc-tagged ERK4 (upper panels)
or myc-tagged ERK3 expression plasmids (lower panels). The
subcellular location of ectopic expressed EGFP-MK5 (or EGFP-
MK5 S115A) was monitored by EGFP ﬂuorescence (green channel)
and the subcellular distribution of ERK3 (or ERK4) is visualized as
the red channel using Alexa Fluor 647-conjugated Myc-tag mouse
monoclonal antibody. Merged images show cytoplasmic colocaliza-
tion of MK5 and ERK3 or ERK4. On average 50 cells expressing
EGFP-MK5 were analysed and representative images are shown.
Similar results were obtained in independent experiments
856 S. Kostenko et al.investigated the effect of MK5 S115A, which is located in
the nucleus, on p53-mediated transcription. HEK293 cells
were therefore cotransfected with a luciferase reporter
plasmid under the control of a promoter consisting of the
TATA box of the adenovirus E1b gene and ﬁve binding
motifs for GAL4, an expression plasmids for GAL4-p53
fusion protein, and plasmid DNA encoding EGFP-MK5,
EGFP-MK5 S115A, or kinase dead EGFP-MK5 T182A.
The last of these mutants also resides exclusively in the
nucleus [22]. Substitution of Ser-115 into Ala reduced the
ability of MK5 to activate p53-mediated transcription by
[50% compared to wild-type MK5 (Fig. 9a). Similarly,
MK5 T182A also displayed a reduced potential to stimu-
late the transcriptional activity of p53 (Fig. 9a).
To test the effects of S115 mutation on cytoplasmic
processes involving MK5, we decided to monitor the
ability of MK5 to phosphorylate Hsp27, which is an in vivo
substrate for MK5 [25]. HEK293 cells were cotransfected
with an expression plasmid for Hsp27 and expression
plasmids for EGFP-MK5, EGFP-MK5 S115D, EGFP-MK5
S115A, and EGFP-MK5 L337A NES. The latter encodes a
constitutive active MK5, but as the L337A mutation resides
in the NES of MK5, the MK5 L337A is exclusively
nuclear. To direct this constitutive active MK5 L337A
mutant into the cytoplasm, a functional NES was added
[22]. Increased Hsp27 phosphorylation at the relevant Ser-
78 residue was obtained in the presence of MK5 S115D
and MK5 L337A NES (Fig. 9b, lanes 3 and 5, respectively)
compared to wild-type and MK5 S115A (Fig. 9b, lanes 2
and 4, respectively). We have previously shown that
cytoplasmic MK5 can affect F-actin rearrangement [25].
We therefore compared F-actin architecture in PC12 cells
expressing either EGFP-MK5 S115A or EGFP-MK5
S115D. Again, we found that the S115A mutant was pre-
dominantly in the nucleus, while the S115D variant was
also detected in the cytoplasm (Fig. 9c). Clear changes in
F-actin remodelling were detected in cells expressing MK5
S115D, but not in cells expressing MK5 S115A. To address
the involvement of HSP27 phosphorylation in MK5
S115D-induced F-actin rearrangement, we overexpressed
Fig. 8 Ser-115 is not implicated in p38
MAPK-induced nuclear export
of MK5. a HeLa cells transfected with EGFP-MK5 or EGFP-MK5
S115A plasmids were left untreated or exposed to sodium arsenite
(250 lM for 120 min). b As in a, but cells were contransfected with
plasmids encoding activated MKK6 (MKK6 E/E) and p38
MAPK. The
subcellular localization of the ectopically expressed MK5 variants
was visualized as described in the legend for Fig. 3. On average 50
cells expressing EGFP-MK5 were analysed and representative images
are shown. Similar results were obtained in independent experiments
PKA-mediated MK5 nuclear export 857the HSP27-3A mutant [25]. Overexpression of this mutant
ablated MK5 S115D-mediated F-actin remodelling
(Fig. 9d). Taken together, these results indicate that
mutations in Ser-115 not only affect the subcellular locali-
zation of MK5, but also the biological properties of this
protein.
Discussion
Several groups, including our own, have shown that MK5
is predominantly nuclear in resting cells, while stimuli
that activate the p38
MAPK and the PKA pathways, as well
as overexpression of MK5 interaction partners cause
Fig. 9 Mutations in Ser-115 affect the biological properties of MK5.
a HEK293 cells were cotransfected with the luciferase plasmid
G5-E1b-LUC, a plasmid encoding GAL4-p53 fusion protein, and
expression vectors for the fusion proteins EGFP-MK5 wild-type
(MK5), EGFP-MK5 S115A (S115A) or kinase dead EGFP-MK5
T182A (T182A). Luciferase activity was determined in three
independent parallel experiments and the p53 transcriptional activity
in the presence of wild-type MK5 was arbitrarily set as 100% and the
activity in the presence of the MK5 S115A or MK5 T182A was
related to this. The experiment was repeated three times and similar
results were obtained. b HEK293 cells were transfected with an
expression plasmid for Hsp27 and with plasmids encoding either
EGFP-MK5 (lane 1), EGFP-MK5 S115D (lane 2), EGFP-MK5
S115A (lane 3), or EGFP-MK5 L337A NES (lane 4). The last of
these is a constitutive active MK5 that is exclusively localized in the
cytoplasm. Phosphorylation of Hsp27 was monitored by western
blotting using a speciﬁc antibody that recognized the relevant
phosphoSer-78 site (top panel). The membrane was stripped and
degree of equality in the expression of the EGFP-MK5 variants was
assayed by western blotting with an anti-PRAK antibody (bottom
panel). c PC12 cells were transfected with plasmids encoding EGFP-
MK5 S115D (top panel) or EGFP-MK5 S115A (bottom panel) and
F-actin was visualized using Alexa Fluor 594 Phalloidin. The
expression of the EGFP-tagged MK5 was visualized by EGFP
ﬂuorescence (green channel). The superimposed images demonstrate
that the architecture of F-actin is changed in cells expressing EGFP-
MK5 S115D, but not in nontransfected cells nor in cells expressing
EGFP-MK5 S115A. d PC12 cells were cotransfected with expression
plasmids for EGFP-MK5 S115D and Hsp27-3A. Hsp27-3A was
visualized using anti-Flag antibody and Alexa 647-coupled secondary
antibody (magenta). MK5 S115D and F-actin were stained as
described above
858 S. Kostenko et al.redistribution of MK5. [19, 20, 22, 24, 26–28, 30, 34, 40].
This subcellular location of MK5 is governed by the
opposing action of functional NLS and NES motifs in MK5
[19, 30]. A model was put forward in which the confor-
mation of MK5 regulates the accessibility of either the
NLS or the NES motif and therefore controls the subcel-
lular location of the protein. A tertiary structure exposing
the NES will promote the cytoplasmic location of MK5,
while MK5 taking on a three-dimensional structure with an
easy accessible NLS will reside in the nucleus [10, 19].
Structural changes, resulting in altered subcellular distri-
bution of MK5 may be induced through interaction with
other proteins or through post-translational modiﬁcations.
In the case of p38
MAPK, ERK3, and ERK4, docking seems
to be necessary and sufﬁcient to trigger nucleocytoplasmic
translocation of MK5 because the catalytic activity of these
proteins was dispensable (Table 1)[ 19, 20, 26–28, 30, 34,
42]. We have recently identiﬁed catalytic subunit Ca of
PKA as a genuine MK5 interaction partner and demon-
strated that activated PKA can induce a transient nuclear
export of MK5 [22]. However, the mechanism by which
PKA regulates the subcellular distribution of MK5 remains
unsolved. In this work we have shown that Ser-115 is a
PKA phosphoacceptor site in vitro and we demonstrated
that replacing this residue by Ala resulted in a MK5 mutant
that remained nuclear in forskolin-treated cells, while
substituting Ser-115 by Asp was sufﬁcient to allow MK5 to
enter the cytoplasm of untreated cells. These results sug-
gest that phosphorylation of MK5 at Ser-115 by PKA may
regulate its subcellular whereabouts and represents a novel
mechanism controlling the location of this protein.
Alignment of the primary sequence of MK2, MK3, and
MK5 revealed that, although the region encompassing Ser-
115 is somewhat conserved between MK2, MK3 and MK5,
there are two major differences. Both MK2 and MK3 lack
the corresponding Ser-115 and the residues C-terminal of
Ser-115 display higher diversity than the N-terminal ones
(Fig. 4b). These differences may explain the dissimilar
behaviour of MK2 and MK5 in response to activation of
the cAMP/PKA pathway. This prompted us to test whether
the addition of this residue and/or replacing the motif
encompassing this residue could affect the subcellular
distribution of MK2. In contrast to MK5, where the phos-
phomimicking S115D mutant is present in both the nucleus
and the cytoplasm, insertion of an Asp residue at the cor-
responding site in MK2 did not alter the subcellular
localization of the MK2 mutant. This suggests that phos-
phomicking is not sufﬁcient to trigger nuclear export of
MK2. While wild-type MK5 is predominantly in the
nucleus, a MK2 hybrid containing the MK5 motif
encompassing Ser-115 was unexpectedly detected both in
the nucleus and the cytoplasm. However, forskolin treat-
ment triggered complete nuclear exclusion of this MK2
mutant, indicating that phosphorylation of Ser-115 in the
MK2 hybrid protein contributes to the regulation of the
subcellular distribution of MK2 in response to forskolin.
The reason why the hybrid MK2 is predominantly in the
cytoplasm of untreated cells remains elusive, but we pos-
tulate that the amino acid substitutions may induce a
conformational change in the chimeric MK2 protein,
resulting in exposure of the NES and subsequent nuclear
export. Additional studies are required to conﬁrm this
suggestion.
The mechanism of PKA-mediated nucleocytoplasmic
distribution of MK5 differs from the other MK5 interaction
partners p38
MAPK, ERK3, and ERK4 (summarized in
Table 1). Nuclear export of MK5 induced by p38
MAPK,
ERK3, and ERK4 does not rely on Ser-115 and occurs
independently of the kinase activity of MK5, as well as
phosphorylation of Thr-182 in the activation loop of MK5.
This is in contrast with PKA-regulated transport, which
required the kinase activity of MK5 and an intact Thr-182.
In analogy with p38
MAPK and ERK3, we found an impor-
tin1/NES-dependency for PKA-triggered nuclear exclusion
of MK5.
ERK3, ERK4 and p38
MAPK can all phosphorylate MK5
at Thr-182 [16, 19, 20, 26–28], but it is not known whether
these enzymes also can phosphorylate Ser-115 and whether
this modiﬁcation contributes to ERK3-, ERK4-, or
p38
MAPK-regulated subcellular localization of MK5. The
ﬁndings that ectopic expression of kinase dead mutants
caused nuclear export of MK5 [19, 20, 26–28, 30, 34] and
that overexpression of ERK3, ERK4 and p38
MAPK still
resulted in nuclear exclusion of MK5 S115A (Figs. 6 and
Table 1 Mechanisms of the subcellular distribution of MK5 mediated by its interaction partners (see text for details)
Interaction partners
p38
MAPK ERK3 ERK4 PKA
Importin1/NES-dependent Yes Yes No Yes
Kinase activity of MK5 Not required Not required Not required Required
Phosphorylation of MK5 at T182A Not required Not required Not required Required
Kinase activity partner Not required Not required Not required Required
Ser-115-dependent No No No Yes
PKA-mediated MK5 nuclear export 8597b) points to a phosphoSer-115-independent mechanism.
Thr-182 is not essential for ERK3-, ERK4-, and p38
MAPK-
induced nuclear export of MK5 because the MK5 T182A
mutant was still excluded from the nucleus when ERK3,
ERK4 or p38
MAPK was overexpressed. PKA-mediated
transport, however, seems to depend on this residue
because no nucleocytoplasmic translocation of MK5
T182A was observed in forskolin-treated cells [22]. For-
skolin may theoretically still trigger phosphorylation of
Ser-115 in MK5 T182A because PKA can phosphorylate
this mutant in vitro and Ca-MK5 T182A complexes can be
detected by coimmunoprecipitation (see supplementary
Figs. S1 and S2). However, forskolin treatment failed to
trigger nuclear export of MK5 T182A, while the MK5
S115D/T182A double mutant could enter the cytoplasm of
untreated cells (Fig. 3c). Similarly, the kinase dead MK5
K51E with a mutation in the ATP-binding pocket was not
excluded from the nucleus after forskolin treatment [22],
while MK5 K51E/S115D was detected in the cytoplasm in
resting cells.
Why can MK5 S115D/T182A and MK5 K51E/S115D
enter the cytoplasm, while MK5 T182A and MK5 K51E
remain in the nucleus upon activation of PKA even though
they possess the putative S115 phosphorylation site? This
difference in subcellular localization behaviour may be
explained by the time point of protein modiﬁcation.
Forskolin treatment of resting cells will trigger posttrans-
lational phosphorylation of MK5, while substitution of Ser-
115 into Asp occurs during translation. The MK5 K51E and
T182A mutants may possess a conformation that renders
Ser-115 inaccessible for posttranslational modiﬁcation by
PKA and/or these mutations may lock MK5 in a confor-
mation that prevents exposure of the NES despite
phosphorylation of Ser-115. In both proposed models, for-
skolin treatment of resting cells will fail to translocate MK5
K51E or MK5 T182A out of the nucleus. At present, we
cannot determine which mechanism might be operational,
but MK5 T182A could still be phosphorylated by PKA in
vitro and still interacts with PKA (see supplementary
Figs. S1 and S2), indicating that Ser-115 is still reachable
by PKA. MK5 K51E/S115D and MK5 S115D/T182A on
the other hand contain amino acid substitutions introduced
during protein synthesis. The nascent MK5 S115D poly-
peptide chain may adopt a structure that exposes the NES or
masks the NLS independently of the incorporation of Lys or
Glu at position 51 (Thr or Ala at position 182, respectively).
The MK5 S115D and MK5 K51E/S115D and MK5 S115D/
T182A proteins may therefore be able to enter the
cytoplasm.
The involvement of p38
MAPK, ERK3 and ERK4 in the
subcellular distribution of MK5 has been shown with
overexpression of these proteins, but the biological rele-
vance of this redistribution of MK5 remains elusive. We
have performed our studies under more physiological
conditions by showing that activation of endogenous PKA
triggers transient nuclear export of endogenous, as well as
ectopically expressed EGFP-MK5 (this study; [22]). We
were able to show that MK5 mediates PKA-induced
F-actin rearrangements by phosphorylating Hsp27 and that
cytoplasmic localization of MK5 is required in this process
[25]. Hence, our results indicate that PKA participates in
activating MK5, causing it to translocate to the cytoplasm,
where it can phosphorylate Hsp27 and modulate F-actin
architecture. In accordance with this, we demonstrated that
MK5 S115D is a more potent Hsp27 kinase than wild-type
MK5. In this study we conﬁrmed the importance of
Ser-115 in regulating the biological functions of this pro-
tein. Previously, Sun et al. [21] had shown that MK5
stimulates the transcriptional activity of p53 through direct
phosphorylation of Ser-37 in the transactivation domain.
We found that compared to wild-type MK5, the MK5
S115A mutant is a weaker stimulator of p53-mediated
transcription. Whether MK5 S115D could enhance the
transcriptional activity of p53 was not addressed. In the
luciferase reporter assay we used, it is difﬁcult to compare
the effect of MK5 S115D and wild-type MK5 on GAL4-
p53-mediated transcription because wild-type MK5 is
predominantly in the nucleus, while a large fraction of
MK5 S115D resides in the cytoplasm, resulting in unequal
nuclear levels of these two proteins. However, because p53
is also implicated in cytoplasmic processes, it is plausible
that the MK5 S115D mutant may affect both the nuclear
and cytoplasmic functions of p53. Hence, our results
indicate that PKA may modulate p53 activity in a
MK5-dependent manner.
Several studies have shown that cAMP levels may
inﬂuence p53 function [43, 44], but the involvement of
MK5 has not been addressed. A recent study showed that
cAMP inhibits doxorubicin-induced phosphorylation of p53
in pre-B acute lymphoblastic leukaemia NALM-6 cells
[45]. Phosphorylation is attenuated at several serines,
including Ser-37 which has been shown to be directly
phosphorylated by MK5 [21]. The mechanism/phosphatase
responsible for cAMP-induced reduction in p53 phosphory-
lation has not been identiﬁed, but it is possible that, at least
for Ser-37, cAMP-triggered nuclear export of MK5 places
MK5 and p53 in different subcellular compartments
resulting in diminished p53 phosphorylation at Ser-37.
PKA-induced subcellular localization and activation of
MK5 offers a mechanism to differentially phosphorylate
nuclear or cytoplasmic substrates of MK5. PKA has also
been shown to control the subcellular localization of the
MAPKAPK RSK1 and hence to modulate the phosphory-
lation of nuclear and cytoplasmic substrates for RSK1 [46].
However, the subcellular localization of RSK1 is not gov-
erned by PKA-mediated phosphorylation of RSK1, but by
860 S. Kostenko et al.binding to the different subunits of PKA [46]. Inactive RSK
interacts with the regulatory subunit of PKA, while active
RSK1 interacts with the catalytic subunit of PKA. The latter
interaction decreases the nuclear accumulation of active
RSK1 and increases its cytoplasmic concentration [46].
Whether Ser-115 is an in vivo phosphoacceptor site
remains to be established. Because no speciﬁc antibody for
phospho-Ser 115 is available, we tried to monitor phos-
phorylation by using phospho-PKA substrate and
phosphoSer antibodies to compare the phosphorylation
pattern of wild-type and S115A MK5. Unfortunately, in
our hands, these antibodies failed to detect phosphorylation
of MK5 and CREB in any of the samples tested. We also
tried the Phos-tag acrylamide gel electrophoresis method
which allows detection of differences in gel electrophoresis
mobility between unphosphorylated and phosphorylated
proteins [47], but again we could not detect any differences
between unphosphorylated and PKA-mediated phosphory-
lation of MK5 and CREB. Other peptide fragments were
weakly phosphorylated by PKA (Fig. 2a). MK5 contains
additional putative phosphorylation sites, including Thr-14,
Ser-43 and Ser-348. Whether these sites are genuine PKA
phosphoacceptor sites is not known, nor has their
involvement in PKA-triggered nuclear export of MK5 been
examined. However, since mutating Ser-115 into Ala
ablates PKA-induced nuclear export, these sites do not
seem to play an essential role in the subcellular behaviour
of MK5 after activation of PKA.
In conclusion, we provide evidence that Ser-115 plays an
essential role in cAMP/PKA-regulated nuclear export of
MK5, and that it also contributes to the regulation of the
activity of MK5. It has been proposed that nucleocyto-
plasmic distribution of MK5 depends on the conformational
structure of MK5, which will reveal or conceal the NES and
NLS (for review see reference [10]). We assume that
phosphorylation of MK5 residue Ser-115 alters the three-
dimensional structure of the protein, exposing the NES and
triggering nuclear export. Our kinetic studies revealed that
PKA-induced nuclear export is transient [22], suggesting
that phosphoSer-115 MK5 may become dephosphorylated
by cytoplasmic protein phosphatase(s) and therefore force
MK5 back to the nucleus by changing its conformation and
hence exposing its NLS. Identiﬁcation of these phospha-
tases and resolving the three-dimensional structure of
MK5 will be very useful to fully comprehend the exact
molecular mechanism governing the subcellular localiza-
tion of MK5.
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